Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope
暂无分享,去创建一个
Peter D. Kwong | John R. Mascola | Hermann Katinger | Gilad Ofek | J. Mascola | H. Katinger | R. Wyatt | P. Kwong | G. Ofek | M. Tang | A. Sambor | Min Tang | Richard Wyatt | Anna Sambor
[1] K. Subbarao,et al. pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN , 2004, Journal of Virology.
[2] H. Katinger,et al. The Long Third Complementarity-Determining Region of the Heavy Chain Is Important in the Activity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 , 2004, Journal of Virology.
[3] Wayne A Hendrickson,et al. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[4] Shibo Jiang,et al. Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes , 2004, Journal of Virology.
[5] Christoph Grundner,et al. Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.
[6] Gennaro Ciliberto,et al. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. , 2003, Journal of molecular biology.
[7] Ping Zhu,et al. Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.
[8] Dennis R. Burton,et al. Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design , 2003, Journal of Virology.
[9] G. McGaughey,et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. , 2003, Biochemistry.
[10] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[11] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[12] Andrew C. R. Martin,et al. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. , 2003, Journal of molecular biology.
[13] B. Korber,et al. HIV sequence compendium 2002 , 2002 .
[14] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[15] G. Lewis,et al. Antigenic Properties of the Human Immunodeficiency Virus Transmembrane Glycoprotein during Cell-Cell Fusion , 2002, Journal of Virology.
[16] Y. Hayek,et al. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. , 2002, Biochemistry.
[17] E. Arnold,et al. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints. , 2002, The journal of peptide research : official journal of the American Peptide Society.
[18] J. Mascola,et al. Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells , 2002, Journal of Virology.
[19] J. Sodroski,et al. Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins , 2002, Journal of Virology.
[20] K. MacDonald,et al. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. , 2002, Vaccine.
[21] H. Katinger,et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.
[22] C. E. Parker,et al. Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.
[23] Paul W. H. I. Parren,et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.
[24] J. Sodroski,et al. Ligand Binding Characteristics of CXCR4 Incorporated into Paramagnetic Proteoliposomes* , 2001, The Journal of Biological Chemistry.
[25] H. Katinger,et al. Cross-Neutralizing Human Monoclonal Anti-HIV-1 Antibody 2F5: Preparation and Crystallographic Analysis of the Free and Epitope-Complexed Forms of its F ab Fragment , 2001 .
[26] Garrett M. Morris,et al. Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design , 2001, Science.
[27] H. Vogel,et al. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. , 2001, Biochemistry.
[28] C Leclerc,et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.
[29] Ying-hua Chen,et al. Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine☆ , 2000, Peptides.
[30] H. Katinger,et al. Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. , 2000, Biotechnology and bioengineering.
[31] Ying-hua Chen,et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody , 2000, Immunological investigations.
[32] R. Blumenthal,et al. Role of the Membrane-Proximal Domain in the Initial Stages of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Membrane Fusion , 1999, Journal of Virology.
[33] J. Shendure,et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. , 1999, Vaccine.
[34] D E McRee,et al. XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.
[35] E. Hunter,et al. A Conserved Tryptophan-Rich Motif in the Membrane-Proximal Region of the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Is Important for Env-Mediated Fusion and Virus Infectivity , 1999, Journal of Virology.
[36] P. D. Kwong,et al. Use of cryoprotectants in combination with immiscible oils for flash cooling macromolecular crystals , 1999 .
[37] H. Katinger,et al. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. , 1998, AIDS research and human retroviruses.
[38] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[39] P. S. Kim,et al. HIV Entry and Its Inhibition , 1998, Cell.
[40] H. Katinger,et al. Baculovirus surface display: construction and screening of a eukaryotic epitope library. , 1998, Nucleic acids research.
[41] C. Weiss,et al. Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.
[42] M. Roederer,et al. 8 color, 10-parameter flow cytometry to elucidate complex leukocyte heterogeneity. , 1997, Cytometry.
[43] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[44] Deborah Fass,et al. Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.
[45] H. Katinger,et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. , 1996, The Journal of general virology.
[46] A. Trkola,et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 , 1996, AIDS.
[47] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[48] G. Cohen,et al. Interactions of protein antigens with antibodies. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[49] A. Trkola,et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.
[50] C. Barbas,et al. Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site , 1995, AIDS.
[51] Q. Sattentau,et al. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.
[52] A. Trkola,et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.
[53] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[54] D R Burton,et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.
[55] A. Trkola,et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS , 1994, Journal of virology.
[56] J. Thornton,et al. Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.
[57] E. Emini,et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[58] A. Trkola,et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. , 1994, AIDS research and human retroviruses.
[59] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[60] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[61] K. Sharp,et al. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.
[62] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[63] I. Wilson,et al. Applications of the streak seeding technique in protein crystallization , 1991 .
[64] Robin A. Weiss,et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.
[65] M. L. Connolly. Analytical molecular surface calculation , 1983 .
[66] E A Merritt,et al. Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.
[67] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.